Navigation Links
Oncothyreon reports full year and fourth quarter 2009 financial results
Date:5/6/2010

Concludes restatement of prior financial results

Company to hold conference call at 4:30 EDT today

SEATTLE, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported financial results for the year and quarter ending December 31, 2009. The Company also announced today that it filed its Annual Report on Form 10-K for the year ended December 31, 2009 (the "2009 Form 10-K"), which concludes the restatement of its historical financial results.

2009 Financial Results

Net loss for the year ended December 31, 2009 was $17.2 million, or $0.76 per basic and diluted share, compared with net income, as restated, of $7.4 million, or $0.38 per basic and diluted share, for the year ended December 31, 2008. The change to net loss from net income was the result of a decrease in revenue to $2.1 million for the year ended December 31, 2009 from $40.3 million for the year ended December 31, 2008, as restated, and a non-cash charge of $6.2 million for the change in fair value of warrant liability in 2009, partially offset by a decrease in operating expenses to $12.9 million in 2009 from $33.2 million in 2008.

The decrease in revenue
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncothyreon reports first quarter 2010 financial results
2. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
3. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
4. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
5. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
6. Oncothyreon announces webcast of third quarter 2009 financial results conference call
7. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
8. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
9. Oncothyreon reports second quarter 2009 financial results
10. Oncothyreon announces closing of $15.0 million registered direct financing
11. Oncothyreon announces webcast of second quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... CHICAGO , July 8 Advanced Life Sciences Holdings, ... discovery, development and commercialization of novel drugs in the therapeutic areas ... preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of ... setting. , , , ...
... drop a toothpick on the head of one particular person ... yet this degree of precision at the cellular level has ... Institute for NanoBioTechnology. Their study was published online in June ... used precise electrical fields as "tweezers" to guide and place ...
... Cardium Therapeutics (NYSE Amex: CXM ) today reported that the Company has ... matters relating to the Company,s exchange listing compliance. , ... http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO ) , , , ... , , ...
Cached Biology Technology:Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 2Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 4Pinpoint precision: Delivering a biochemical payload to 1 cell 2Pinpoint precision: Delivering a biochemical payload to 1 cell 3Cardium Regains Listing Compliance With NYSE Amex 2Cardium Regains Listing Compliance With NYSE Amex 3Cardium Regains Listing Compliance With NYSE Amex 4
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... issue of The American Naturalist, Tom E. X. Miller, ... the University of Nebraska, Lincoln) examined herbivore dynamics, specifically ... , Plant-insect ecologists typically attribute the differences to ... plant tissues. However, the researchers found that cactus-feeding insects ...
... role in longevity, with longer-lived rodents showing significantly lower ... new study has found. , The study further strengthens ... shorter its life, and vice versa, said Mario Pinto, ... regulate metabolic rate. , "Thyroid hormones are key ...
... international Census of Marine Life (CoML), a team of ... explore coral reef biodiversity in the largest fully protected ... National Monument. Led by the National Oceanic and ... funding from NOAA's Coral Reef Conservation Program and the ...
Cached Biology News:Longer-lived rodents have lower levels of thyroid hormone 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 3
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Biology Products: